NCYT:LON
Novacyt
39,00 GBX
arrow_upward
+0,52%(+0,20) 1G
13 ott, 16:35:08 GMT+1 · GBX
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per NCYT in corso…
Apertura
39,34 GBX
Massimo
40,40 GBX
Minimo
39,00 GBX
Cap. mercato
34,02 Mln
Vol. medio
109,27K
Volume
76,22K
Max 52 sett.
86,00 GBX
Min 52 sett.
26,60 GBX
Azioni in circolazione
37,66 Mln
N. di dipendenti
228
Apertura
39,34 GBX
Massimo
40,40 GBX
Minimo
39,00 GBX
Cap. mercato
34,02 Mln
Vol. medio
109,27K
Volume
76,22K
Max 52 sett.
86,00 GBX
Min 52 sett.
26,60 GBX
Azioni in circolazione
37,66 Mln
N. di dipendenti
228
Articoli giornalistici
Da fonti web e partner giornalistici
MarketScreener Italia
·
58 minuti fa
S&P 500 stabile mentre i produttori di chip arretrano e arrivano i risultati delle banche
Yellow.com
·
13 minuti fa
La corsa dell’S&P 500 ora dipende dalle indicazioni sull’AI mentre entra nel vivo la stagione delle trimestrali
Profilo
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Informazioni su Novacyt